Year: 2024

Roadzen Inc. Announces Pricing of Public Offering

Written by Customer Service on December 16, 2024. Posted in Public Companies.

NEW YORK, Dec. 15, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN), (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced the pricing of an underwritten public offering of 2,000,000 ordinary shares (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) at a public offering price of $1.25 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of $2,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the ordinary shares (and/or Pre-funded Warrants) are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares (and/or Pre-funded Warrants) at the public offering price less discounts and...

Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology

Written by Customer Service on December 16, 2024. Posted in Mergers And Acquisitions.

The healthcare analytical testing services market is growing due to rising clinical trials, biosimilar focus, increased outsourcing, and the impact of COVID-19. Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global healthcare analytical testing services market size will reach a value of USD 15.55 Billion by 2031, with a CAGR of 11.2% during the forecast period (2024-2031). The market’s main driving factors are the number of companies in the pharmaceutical and medical device industries that outsource analytical testing services, increased clinical trials in need of analytical testing, and the rising emphasis on biosimilars. The industry has grown as a result of the COVID-19 pandemic. Additionally, since the pandemic, the market has seen a quick development in medications and treatments for its prevention,...

Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology

Written by Customer Service on December 16, 2024. Posted in Mergers And Acquisitions.

The stem cell banking market is growing due to advancements in cryopreservation, cell bank prep, monoclonal antibodies, and the rising adoption of stem cell therapy. Westford, USA, Dec. 15, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the global stem cell banking market share will reach a value of USD 18.65 Billion by 2031, with a CAGR of 18.30% during the forecast period (2024-2031). As cryopreservation and cell bank preparation techniques are getting advanced, the stem cell banking market is expanding rapidly. Besides, the market is growing due to the increased application of stem cell treatment and the trend of monoclonal antibodies with effective biopharmaceuticals. Furthermore, with the fact that more couples are opting for children at a later stage in life, late parenting is on the rise, and it has generated interest in...

Brazil Potash Schedules Investor Call

Written by Customer Service on December 15, 2024. Posted in Public Companies.

Call Scheduled for 5 PM ET on Monday, December 16, 2025 MANAUS, Brazil, Dec. 15, 2024 (GLOBE NEWSWIRE) — Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE-American: GRO), an exploration and development company existing under the laws of Ontario, Canada with a potash mining project located in the state of Amazonas, Brazil, today announced that management will host a webcast at 5 PM ET on Monday, December 16, 2024. Interested investors and other parties can listen to the webcast by logging onto the Investor Relations section of the Company’s website at https://ir.brazilpotash.com. About Brazil Potash Brazil Potash is an exploration and development company with a potash mining project (the “Autazes Project”) located in the state of Amazonas, Brazil. The Company’s technical operations are based in Autazes, Amazonas,...

Pharming announces public cash offer to the shareholders of Abliva AB

Written by Customer Service on December 15, 2024. Posted in Mergers And Acquisitions.

Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies...

Avance Gas Holding Ltd: Completed the tenth VLGC delivery to BW LPG successfully

Written by Customer Service on December 15, 2024. Posted in Public Companies.

Hamilton, Bermuda. December 15, 2024Avance Gas Holding Ltd (“Avance Gas” or “Company”) (OSE:AGAS) refers to the announcement on August 15, 2024, regarding the sale of its VLGC fleet, consisting of twelve vessels, to BW LPG Ltd (“BW LPG” or “Buyer”). Avance Gas announces today the tenth VLGC delivery, the 2015-built scrubber-fitted vessel, Breeze. In connection with the delivery, 1.35 million shares in BW LPG were issued by the Buyer to Avance Gas. Additionally, the Company also received net cash proceeds of approximately $21.5 million after repayment of outstanding debt. Following the delivery, Avance Gas owns 15.791 million shares in BW LPG corresponding to a 10.14% ownership share. The two remaining vessels are scheduled for delivery to BW LPG by year-end, with press releases to be issued...

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

Written by Customer Service on December 14, 2024. Posted in Public Companies.

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk’s subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S. The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here. Novo Nordisk now expects the acquisition to be completed in the coming days. Upon completion, the acquisition is expected to impact the financial outlook as issued on 6...

DEMESNE RESOURCES LTD. ANNOUNCES CLOSING OF A SECOND TRANCHE OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT FINANCING

Written by Customer Service on December 14, 2024. Posted in Public Companies.

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Dec. 13, 2024 (GLOBE NEWSWIRE) — Demesne Resources Ltd. (CSE:DEME) (OTCQB:DEMRF) (“Demesne” or the “Company”) is pleased to announce that it has completed the second tranche (the “Second Tranche”) of its previously announced non-brokered private placement financing (the “Offering”). Pursuant to the Second Tranche, the Company issued 3,495,603 common shares of the Company (“Common Shares”), at a price of $0.25 per Common Share for gross proceeds of approximately $873,901.The Company plans to complete a subsequent tranche of the Offering, for gross proceeds of up to $839,599 in December 2024.In connection with the Second Tranche, the Company paid finder’s fees to eligible finders consisting of $1,050 in cash and 4,200 Common...

Global Uranium Corp. Announces Marketing Program

Written by Customer Service on December 14, 2024. Posted in Public Companies.

CALGARY, Alberta, Dec. 13, 2024 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTCQB: GURFF | FRA: Q3J) (the “Company“) announces that it has engaged RedChip Companies Inc. (“RedChip”) (address: 31 E Horatio Ave, Suite #100, Maitland, FL 32751; email: info@redchip.com) to provide marketing services for an anticipated period of 14 days commencing on December 17th, 2024. RedChip will begin a National CNBC campaign for the Company by writing and producing a 30 second TV ad to air 40 times on CNBC National TV over a 2-week period. The Company will pay a one-time fee of USD $45,000.00 (plus GST) to RedChip. The Company will not issue any securities to RedChip as compensation for its marketing services. As of the date hereof, to the Company’s knowledge, RedChip (including its directors and officers) does not own any...

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Written by Customer Service on December 13, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “Units”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals